AU1166100A - Use of a substance binding with the peripheral benzodiazepin receptor for treating skin stress - Google Patents
Use of a substance binding with the peripheral benzodiazepin receptor for treating skin stress Download PDFInfo
- Publication number
- AU1166100A AU1166100A AU11661/00A AU1166100A AU1166100A AU 1166100 A AU1166100 A AU 1166100A AU 11661/00 A AU11661/00 A AU 11661/00A AU 1166100 A AU1166100 A AU 1166100A AU 1166100 A AU1166100 A AU 1166100A
- Authority
- AU
- Australia
- Prior art keywords
- pbr
- substance
- composition
- use according
- binds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000002093 peripheral effect Effects 0.000 title claims abstract description 10
- 239000000126 substance Substances 0.000 title claims description 27
- 239000000203 mixture Substances 0.000 claims abstract description 47
- 230000000699 topical effect Effects 0.000 claims abstract description 11
- 238000011282 treatment Methods 0.000 claims abstract description 10
- 102000004300 GABA-A Receptors Human genes 0.000 claims abstract description 6
- 108090000839 GABA-A Receptors Proteins 0.000 claims abstract description 6
- 239000013543 active substance Substances 0.000 claims description 12
- 239000002537 cosmetic Substances 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 7
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 5
- 150000001261 hydroxy acids Chemical class 0.000 claims description 5
- 238000000605 extraction Methods 0.000 claims description 4
- 238000000855 fermentation Methods 0.000 claims description 4
- 230000004151 fermentation Effects 0.000 claims description 4
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 3
- 239000000556 agonist Substances 0.000 claims description 3
- 230000000144 pharmacologic effect Effects 0.000 claims description 3
- 241000894007 species Species 0.000 claims description 3
- 230000037303 wrinkles Effects 0.000 claims description 3
- 241000187654 Nocardia Species 0.000 claims description 2
- 241000187747 Streptomyces Species 0.000 claims description 2
- 125000004122 cyclic group Chemical group 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 229960003471 retinol Drugs 0.000 claims description 2
- 235000020944 retinol Nutrition 0.000 claims description 2
- 239000011607 retinol Substances 0.000 claims description 2
- 229920006395 saturated elastomer Polymers 0.000 claims description 2
- 150000004492 retinoid derivatives Chemical class 0.000 claims 2
- 206010041303 Solar dermatitis Diseases 0.000 claims 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims 1
- 229930002330 retinoic acid Natural products 0.000 claims 1
- 229960001727 tretinoin Drugs 0.000 claims 1
- 239000003446 ligand Substances 0.000 abstract description 22
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 45
- 239000002609 medium Substances 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 19
- 108020003175 receptors Proteins 0.000 description 19
- 102000005962 receptors Human genes 0.000 description 19
- 239000000284 extract Substances 0.000 description 16
- 229920005989 resin Polymers 0.000 description 15
- 239000011347 resin Substances 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- 239000000725 suspension Substances 0.000 description 13
- 238000012360 testing method Methods 0.000 description 11
- 230000005764 inhibitory process Effects 0.000 description 10
- 210000002510 keratinocyte Anatomy 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 206010015150 Erythema Diseases 0.000 description 9
- 238000010790 dilution Methods 0.000 description 9
- 239000012895 dilution Substances 0.000 description 9
- 231100000321 erythema Toxicity 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 230000004224 protection Effects 0.000 description 8
- 210000003491 skin Anatomy 0.000 description 8
- 230000035882 stress Effects 0.000 description 8
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 7
- 101150017888 Bcl2 gene Proteins 0.000 description 7
- 206010030113 Oedema Diseases 0.000 description 7
- 238000012258 culturing Methods 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 210000002615 epidermis Anatomy 0.000 description 6
- 238000011081 inoculation Methods 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 239000002028 Biomass Substances 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 239000013587 production medium Substances 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101000610620 Homo sapiens Putative serine protease 29 Proteins 0.000 description 3
- 102100040345 Putative serine protease 29 Human genes 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229960003529 diazepam Drugs 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 229920003053 polystyrene-divinylbenzene Polymers 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- AUZQQIPZESHNMG-UHFFFAOYSA-N 3-methoxysalicylic acid Chemical compound COC1=CC=CC(C(O)=O)=C1O AUZQQIPZESHNMG-UHFFFAOYSA-N 0.000 description 2
- WHSXTWFYRGOBGO-UHFFFAOYSA-N 3-methylsalicylic acid Chemical compound CC1=CC=CC(C(O)=O)=C1O WHSXTWFYRGOBGO-UHFFFAOYSA-N 0.000 description 2
- 108010063104 Apoptosis Regulatory Proteins Proteins 0.000 description 2
- 102000010565 Apoptosis Regulatory Proteins Human genes 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 229940124091 Keratolytic Drugs 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 230000008045 co-localization Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 210000004209 hair Anatomy 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000001530 keratinolytic effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000002438 mitochondrial effect Effects 0.000 description 2
- 210000001700 mitochondrial membrane Anatomy 0.000 description 2
- 239000006916 nutrient agar Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- -1 polydimethylsiloxane Polymers 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 210000000434 stratum corneum Anatomy 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 239000012137 tryptone Substances 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- OXIKLRTYAYRAOE-CMDGGOBGSA-N (e)-3-(1-benzyl-3-pyridin-3-ylpyrazol-4-yl)prop-2-enoic acid Chemical compound N1=C(C=2C=NC=CC=2)C(/C=C/C(=O)O)=CN1CC1=CC=CC=C1 OXIKLRTYAYRAOE-CMDGGOBGSA-N 0.000 description 1
- IXIGWKNBFPKCCD-UHFFFAOYSA-N 2-hydroxy-5-octanoylbenzoic acid Chemical compound CCCCCCCC(=O)C1=CC=C(O)C(C(O)=O)=C1 IXIGWKNBFPKCCD-UHFFFAOYSA-N 0.000 description 1
- IKRKINIKITZMKG-UHFFFAOYSA-N 2-hydroxy-5-octylbenzoic acid Chemical compound CCCCCCCCC1=CC=C(O)C(C(O)=O)=C1 IKRKINIKITZMKG-UHFFFAOYSA-N 0.000 description 1
- GFOUVESKDMJIJA-UHFFFAOYSA-N 4-heptoxy-2-hydroxybenzoic acid Chemical compound CCCCCCCOC1=CC=C(C(O)=O)C(O)=C1 GFOUVESKDMJIJA-UHFFFAOYSA-N 0.000 description 1
- VHDBCRXSHLVFGR-UHFFFAOYSA-N 5-decanoyl-2-hydroxybenzoic acid Chemical compound CCCCCCCCCC(=O)C1=CC=C(O)C(C(O)=O)=C1 VHDBCRXSHLVFGR-UHFFFAOYSA-N 0.000 description 1
- NCYSBHWOHLGEQN-UHFFFAOYSA-N 5-dodecanoyl-2-hydroxybenzoic acid Chemical compound CCCCCCCCCCCC(=O)C1=CC=C(O)C(C(O)=O)=C1 NCYSBHWOHLGEQN-UHFFFAOYSA-N 0.000 description 1
- 241000186361 Actinobacteria <class> Species 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 208000006877 Insect Bites and Stings Diseases 0.000 description 1
- 206010024769 Local reaction Diseases 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101710157899 Protein CrtK Proteins 0.000 description 1
- 206010037083 Prurigo Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 230000002292 Radical scavenging effect Effects 0.000 description 1
- 241000191025 Rhodobacter Species 0.000 description 1
- 241000191043 Rhodobacter sphaeroides Species 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 229940076005 apoptosis modulator Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 1
- 229960003120 clonazepam Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 239000002577 cryoprotective agent Substances 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000006355 external stress Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- CBKLICUQYUTWQL-XWGBWKJCSA-N methyl (3s,4r)-3-methyl-1-(2-phenylethyl)-4-(n-propanoylanilino)piperidine-4-carboxylate;oxalic acid Chemical compound OC(=O)C(O)=O.CCC(=O)N([C@]1([C@H](CN(CCC=2C=CC=CC=2)CC1)C)C(=O)OC)C1=CC=CC=C1 CBKLICUQYUTWQL-XWGBWKJCSA-N 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000006540 mitochondrial respiration Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- LWGJTAZLEJHCPA-UHFFFAOYSA-N n-(2-chloroethyl)-n-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 230000010807 negative regulation of binding Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 230000003711 photoprotective effect Effects 0.000 description 1
- 208000017983 photosensitivity disease Diseases 0.000 description 1
- 230000029553 photosynthesis Effects 0.000 description 1
- 238000010672 photosynthesis Methods 0.000 description 1
- 230000000243 photosynthetic effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000010773 plant oil Substances 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000013812 regulation of steroid biosynthetic process Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- 229940108325 retinyl palmitate Drugs 0.000 description 1
- 235000019172 retinyl palmitate Nutrition 0.000 description 1
- 239000011769 retinyl palmitate Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000013391 scatchard analysis Methods 0.000 description 1
- 238000005201 scrubbing Methods 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000028070 sporulation Effects 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000000438 stratum basale Anatomy 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/70—Biological properties of the composition as a whole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/803—Physical recovery methods, e.g. chromatography, grinding
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/822—Microorganisms using bacteria or actinomycetales
- Y10S435/886—Streptomyces
Abstract
A composition containing a peripheral benzodiazepine receptor ligand for topical use in the treatment of cutaneous stress.
Description
WO 00/28947 1 PCT/FR99/02761 USE OF A SUBSTANCE WHICH BINDS TO THE PERIPHERAL BENZODIAZEPINE RECEPTOR IN THE TREATMENT OF CUTANEOUS STRESS The present invention relates to a 5 composition for topical use containing a ligand for peripheral benzodiazepine receptors. The invention relates to the use of a substance which binds specifically to the peripheral benzodiazepine receptor (PBR) for the manufacture of a 10 composition for the prophylaxis or treatment of cutaneous stress. The invention also relates to compositions containing these substances. These compositions may be cosmetic or pharmaceutical, and in particular topical 15 dermatological compositions. The term "cutaneous stress" means the various situations which may cause damage in particular to the epidermis, irrespective of the agent causing this damage. This agent may be inside and/or outside the 20 body, for instance a chemical or free-radical agent or alternatively an external agent such as ultraviolet radiation. The composition according to the invention is thus intended to prevent and combat skin irritation, 25 dry patches, erythema, dysesthetic sensations, sensations of heating, pruritus of the skin and/or mucous membranes, and ageing, and may also be used in skin disorders such as, for example, psoriasis, 2 pruriginous diseases, herpes, photodermatitis, atopic dermatitis, contact dermatitis, lichens, prurigo, pruritus, insect bites, in fibrosis and other disorders of collagen maturation, in immunological disorders or 5 in dermatological conditions such as eczema. The PBR ligand, also referred to as "substance", contained in the composition may be a non peptide compound, a peptide, a cell extract or tissue extract of animal or plant origin or a product obtained 10 by fermenting a microorganism, for example fermenting a bacterium or fungus. Many PBR ligands are disclosed in the literature. Examples which may be mentioned include Ro 5-4864 or chlorodiazepam, Ro 5-2807 or diazepam and 15 PK 11195, or reference may be made to the article Peripheral Benzodiazepine Receptors, Ch. III, J.J. Bourguignon, Ed. E. Giesen - Crouse, Academic Press. PBR is an 18-kd protein located on the outer membrane of the mitochondria of peripheral tissues. It 20 consists of five transmembrane domains and of a carboxy-terminal portion directed towards the cytosol. Several functions are attributed to PBR depending on the nature of the tissue under consideration: regulation of steroidogenesis, biosynthesis of heme, 25 cell differentiation and growth, control of mitochondrial respiration (Krueger KE, Biochimica and Biophysica Acta 1995, 1241, 453-470). Although its precise function has not yet been fully elucidated, 3 several recent experimental data suggest that PBR might play a fundamental role in regulating the processes of programmed cell death and in protection against free radicals. 5 It has been shown that PBR is in fact closely associated at the mitochondrial level with apoptosis regulatory proteins such as Bcl2 which prevents rupture of the mitochondrial membrane potential, thus preventing the apoptosis induced in particular by the 10 production of reactive oxygenated radicals (Marchetti P. et al., J. Exp. Med. 1996, 184, 1155 1160); (Marchetti P. et al., J. Immunol. 1996, 157, 4830-4836). In the context of the present invention, the 15 protective role of PBR against free radicals was directly observed on cells of hematopoietic origin for which a close correlation between the PBR density and the protection against free radicals was demonstrated. Furthermore, in this same study, it was demonstrated 20 that the transfection of PBR into cells lacking this receptor gives protection against the damage caused by oxygenated species (Carayon P. et al., Blood 1996, 87, 3170-3178). Several literature data suggest that PBR 25 might play an important role in regulating apoptosis processes and in protecting cells against damage caused by free radicals.
4 Recent phylogenic studies reinforce this novel notion that PBR acts as an apoptosis modulator involved in antioxidant functions. The reason for this is that significant similarities exist between PBR and 5 the protein CrtK of Rhodobacter sphaeroides, a photo synthetic bacterium. This bacterial protein which functions as a photosensitive oxygen detector, regulates the expression of the genes involved in photosynthesis in response to environmental changes in 10 oxygen tension and in light intensity. The comparison between PBR and CrtK reveals 35% identity and a conservation of sequence between these two proteins which diverged in the phylogeny two billions years ago. This homology suggests a highly specialized and 15 conserved function of PBR which appears to be similar to that of CrtK in the bacterium. Specifically, it has recently been demonstrated that mammalian PBR transfected into Rhodobacter CrtK mutants complements the oxygen-detecting function of CrTK. Thus, this study 20 suggests a key role of PBR in the transduction of oxygen-dependant signals (Yeliseev AA., et al., Proc. Natl. Acad. Sci. 1997, 94, 5101-5106). However, to date, no substance has ever been precisely indicated as a specific ligand for cutaneous 25 PBR receptors, which is all the more reason why no topically active substance which binds specifically to the PBR receptors has ever been disclosed in the literature.
5 It has now been shown, in the context of the present invention, that PBR is abundantly expressed in the skin within the various cell compartments of which it is composed: keratinocytes, Langerhans cells, hair 5 follicles and endothelial cells of the dermal vascular system. In the skin, the expression of PBR follows an increasing gradient from the basal layer to the horny layer. This noteworthy organization which favors the differentiated cells of the epidermis that are the most 10 exposed to external stresses is undoubtedly of primordial physiological importance for protecting the most vulnerable areas of the epidermis. Subcellular studies performed by confocal microscopy indicate, as expected, a colocalization of PBR with Bcl2 in the 15 mitochondrian. Histological studies on skin sections have revealed a surprising distribution of PBR (Figures 1 and 2). Specifically, the expression of this receptor in the epidermis follows a gradient of increasing 20 density from the basal layers to the most differentiated layers of keratinocytes. This highly organized spatial distribution which favors, in terms of density, the outermost and thus the most exposed cells of the epidermis, leads to the assumption that 25 PBR in the skin might represent a natural protection system against free radicals generated by exposure to ultraviolet radiation. The concomitant observation that the distribution of the anti-apoptotic protein Bcl2 6 obeys a strictly inverse gradient suggests a compensatory role of PBR in preserving the cells that are most differentiated. This set of data which suggest a protective 5 function of PBR, more particularly in the epidermis, has led to the discovery of natural or synthetic ligands, showing that their interaction with PBR could be beneficial in various situations of cutaneous stress induced by chemical or free-radical agents or 10 alternatively following an exposure to UV. Thus, according to one of its aspects, the present invention relates to the use of a ligand which is specific for PBR, Ro 5-4864, in cutaneous stress. This ligand is a PBR agonist. 15 According to another aspect of the invention and on the basis of these observations, a screening directed toward finding natural PBR ligands was undertaken and made it possible to isolate several fractions capable of interacting with this receptor. 20 The potentially protective effect of these natural ligands was then evaluated in various tests inducing a cutaneous stress and in particular in tests of cutaneous erythema induced by UV irradiation. Radical scavenging properties and skin repair capacities were 25 also investigated. Biochemical and pharmacological tests were used to demonstrate the activity and advantage of the substances in various situations of cutaneous stress.
7 The tests performed with PBR were aimed at showing its potential involvement in regulating apoptotic processes and in preserving skin cells against various deleterious stress situations. 5 EXAMPLE 1 Immunohistological studies of cutaneous localization of PBR A Western blot analysis made it possible to demonstrate the abundant presence of PBR on six 10 different lines of human keratinocytes and on normal human skin (Figure 1), using specific anti-PBR antibodies Ac 8D7 (anti-PBR mouse mAb, isotype IgGl, Dussossoy et al., Cytometry, 1996, 24:39-48). At the subcellular level, the analyses performed by confocal 15 microscopy confirm a colocalization of PBR at the mitochondrial level in keratinocytes (Figure 2). An immunohistological study performed on a normal human epidermal section using the same antibody reveals a very particular organization since the 20 expression of PBR increases from the stratum basale to the stratum corneum. This receptor is thus abundantly present on the keratinocytes that are most differentiated, located directly under the stratum corneum (Figure 3). 25 EXAMPLE 2 Binding and specificity studies The binding studies were performed on the keratinocyte line A-431 (human epidermoid carcinoma 8 (ATCC, CRL-1555)) by displacement of the reference ligand [ 3 H]-PK11195. Scatchard analysis indicates a single binding site, a density of about 470 000 receptors per cell and high affinity of the ligand 5 (KD = 1.5 nM) (Figure 4). The specificity of the binding to the peripheral receptor borne by the keratinocytes is confirmed by the pharmacological studies which show a decreasing efficacy of the displacement of the reference peripheral ligand 10 (PK 11195) by the following ligands: Ro 5-4864 = (IC 50 = 25 nM) > diazepam (IC 50 = 100 n1M) >>> clonazepam (inactive at 3 200 nM). It is recalled that this last compound is a ligand of the central receptor for benzodiazepines, diazepam is mixed and Ro 5-4864 is 15 specific for PBR (Figure 5). EXAMPLE 3 Involvement of PBR in protection against oxygenated radicals Two types of experiment are described in 20 Figure 6. The first consists in comparing different lines of lymphoid or myeloid origin as regards their ability to withstand the toxicity of oxygenated radicals in relation with their level of expression of PBR. The results indicate a very strong correlation 25 between the number of PBR sites per cell and the resistance to the toxicity induced by H 2 0 2 . There is also a similar correlation when, this time, the level of expression of Bcl2, a protein known to protect cells 9 against oxidative damage, is considered. These data, combined with the fact that Bcl2 and PBR are proteins located on the outer mitochondrial membrane, suggest that they may have common functions in cell protection. 5 Interestingly, although the expression of PBR follows a density gradient which increases from the basal layer to the limit of the horny layer, the literature data indicate an inverse phenomenon for the expression of Bcl2, suggesting that during the differentiation of 10 keratinocytes, PBR may take over from Bcl2 as regards the functions of protection against free radicals. In the second experiment, the possible role of PBR in protection against the toxicity of free radicals is reinforced by the demonstration of the 15 better viability, in the presence of H 2 0 2 , of PBR+ transfected Jurkat cells in comparison with homologous PBR- cells. EXAMPLE 4 The anti-apoptotic activity of the active 20 agents was measured on human keratinocytes and on fibroblasts (ATCC) which were inoculated in 35 mm Petri dishes (5 x 105 cells/well) in DMEM (Dubelco's Mode Eagle Medium) supplemented with 10% fetal calf serum and left to proliferate to the point of confluence. 25 This culture medium is then drawn off, the cells are rinsed and 0.1% fetal calf serum is added in the presence of a saline solution. Increasing concentrations of the substance to be studied are 10 added. Twenty four hours later, the apoptosis is measured with an ELISA (enzyme-linked immunosorbent assay) assay kit. Keratinocytes were subjected to ultraviolet 5 radiation of type B (UVB) at a dose of 250 J/m2 for 16 hours (J. Invest. Dermatol. 1995, 104: 922-927). In the presence of the PBR ligand Ro 5-4864, it was shown that the cell impairment processes induced by the irradiation are prevented in a ligand concentration 10 range of between 10 nM and 10 gm. EXAMPLE 5 The photoprotective effect of the ligand was evaluated by cutaneous application to albino guinea pigs. 15 The cutaneous topical route is used in order to reproduce the conditions of utilization in man. Harley guinea pigs, from Charles River France, Saint Aubin les Elbeuf, 76410 Cl6on, France, are used. 20 The animals were shaved and the hair on the right and left hind flanks was then plucked 24 hours before the start of the treatment. The animals were irradiated immediately before the first treatment. The energy is checked 25 before each irradiation performed on the right and left flanks, in the UVB spectrum at a dose of 4 000 mJ/cm2 The right flank of the animals was treated with 0.2 ml of ligand solution immediately after 11 irradiation and then 2 and 5 hours after irradiation. The left flank will not be treated. A Xeron high pressure vapor lamp (IDEM 300) will produce the irradiation. 5 The local reactions are read before treatment and then 5 and 24 hours after irradiation. Erythema and edema were evaluated as follows: Erythema 0 no erythema; 1 very mild, barely perceptible 10 erythema; 2 distinct, pale pink erythema; 3 distinct, bright red erythema; 4 particularly intense erythema Edema 0 no edema; 1 very mild edema (barely visible); 2 mild edema (contours well defined and swelling apparent); 3 15 moderate edema (thickness of about 1 mm); 4 serious edema (thickness greater than 1 mm and area greater than the area of application). Examples of natural ligands for the PBR receptor which are produced by fermentation are 20 described below with their activity. A screening carried out on microorganism extracts performed on solid or liquid medium made it possible to select three strains of microorganisms (microscopic fungi and bacteria). 25 The three strains selected after various studies performed to optimize the conditions for producing significant amounts of culture extracts having good activities in the test for measuring the 12 interaction with the PBR receptor, have the references SRL 4988, SRL 5186 and SRL 5189. The above three strains were filed at the CNCM of the Institut Pasteur: date of 27 August 1999 5 with the respective serial numbers 1-2305, 1-2306 and 1-2307. The strain SRL 4988 classified as Nocardia species, isolated from a soil sample, has the following ecologico-physiological properties, determined after 10 culturing for two weeks at 28 0 C on ISP2 medium: negative phototroph, chemo-organotroph, mesophile and negative halophile. It is immobile and has open, non verticillate whorls. The strain SRL 5186 classified as 15 Streptomyces species, isolated from a soil sample, has the following ecologico-physiological properties, determined after culturing for two weeks at 28 0 C on ISP2 medium: negative phototroph, chemo-organotroph, mesophile and negative halophile. It is immobile and 20 has flexible, biverticillate hyphae. The strain SRL 5189 classified as Actinosinnema species has the following ecologico physiological properties, determined after culturing for two weeks at 28 0 C on ISP2 medium: negative 25 phototroph, chemo-organotroph, mesophile, negative halophile. It is immobile and has flexible, monoverticillar hyphae.
13 These strains, and also their productive mutants, thus constitute a further subject of the invention. After culturing on nutrient agar medium and 5 several successive subculturings which produce an abundant and pure culture, a storage batch 0 of the stock strain and then primary and secondary inoculation batches are prepared. To do this, a spore suspension is prepared 10 from a culture on nutrient agar medium in a Petri dish and from an uptake medium; this medium contains a cryoprotective agent to ensure good viability of the spores during the storage by freezing. The spore suspension obtained is distributed 15 into cryotubes which will be stored at -80OC: these tubes constitute batch 0. By following the same protocol, but using a tube from batch 0, a primary inoculation batch is prepared. Next, again according to the same protocol, a 20 secondary inoculation batch is prepared from a primary inoculation cryotube. Manufacture of the inoculation batches 0, 1 and 2 ensures long-lasting availability of the strain and thus of the desired activity. The culturing of these three strains for obtaining natural 25 ligands of the PBR receptor may be carried out in a similar manner with the usual aerobic culture means, i.e. liquid media in fermenters of any volume with in line monitoring of the pH and the aeration.
14 EXAMPLE A SRL 4988 As an example of culturing in conical flasks for the strain SRL 4988: a secondary inoculation tube is used to inoculate Petri dishes prepared with a 5 medium for promoting actinomycetes sporulation according to the composition: Glucose 20 g Soyoptim (SIO) 10 g CaCO 3 (OMYA) 3 g Agar type E 20 g Distilled water qs 1 1 The cultures are incubated in dishes for 5 10 days at 280C. A spore suspension is then obtained by adding 10 ml of a liquid medium of the composition below to each Petri dish: Glucose 30 g Soyoptim (SIO) 10 g Tryptone U.S.P. (Biokar) 4 g Yeast extract (Difco) 8 g NaCl 2.5 g CaCO 3 5 g Casein hydrolyzate 5 g Soybean papain peptone 5 g 15 the pH of which is adjusted to 7.0 before sterilization. 5 ml of the spore suspensions are used to inoculate sterile 250 ml flasks, containing 50 ml of 5 the same medium, which constitute the precultures, incubated in a warm chamber at 28 0 C on a shaker with shelves, or in an autonomous incubator, the rotation speeds in either of the systems being set at 210 rpm. After shaking for two days, the preculture 10 flasks are used to inoculate the actual culture flasks at a rate of 5 ml of preculture medium per 500 ml conical flask containing culture medium (100 ml) having the composition: Glycerol 10 g Soluble starch 30 g Soyoptim 15 g Tryptone 2 g Yeast extract 5 g CaCO 3 5 g Trace element solution 10 ml Water qs 1 1 pH 7 15 Composition of the trace element solution used: 16 FeSO 4 7 H 2 0 1.0 g MnSO 4 4 H 2 0 1.0 g CaCl 2 2 H 2 0 0.025 g CaCl 2 2 H 2 0 0.10 g
H
3 B0 3 0.56 g
(NH
4
)
6 Mo 7 0 24 - 4 H 2 0 0.002 g ZnSO 4 - 7 H 2 0 0.20 g Water qs 1 1 Thus, in this specific case, five preculture flasks were used to inoculate 40 culture flasks with 100 ml of culture medium per 500 ml conical flask, 5 which, after shaken culturing for 6 days at 28 0 C in a warm chamber on a rotary shaker set at 210 rpm, give 4 liters of bacterial suspension. The 4 liters of fermentation broth are centrifuged several times, at a temperature of 4 0 C and 10 under a regime of 13 500 rpm (i.e. 27 500 x g with the rotor used), in order to separate.out the biomass, i.e. the pellet combining the cells from the culture supernatant consisting mainly of water from the nutrient medium used and containing in solution 15 residues of components of the nutrient medium and also metabolites produced and excreted by the bacterial cells during the various phases of their growth. The biomasses and supernatants are then frozen at -20 0 C. 20 17 EXTRACTION OF THE NATURAL LIGANDS OF THE PBR RECEPTOR The 4 liters of thawed supernatant are placed in a 10 liter beaker. 400 g of Amberlite XAD 16 poly styrene-divinylbenzene resin (Rohm & Haas) are added to 5 the solution. The suspension is shaken using a motor equipped with a paddle shaft, rotating at 20 rpm, for 15 hours. The solution is then filtered, the filtrate is removed and the drained resin is taken up in 1 liter of methanol. This mixture is stirred gently for 1 hour. 10 The resin is again filtered off and retreated in an identical manner with 1 liter of methanol. During a third operation, the resin is retreated, this time with 1 liter of acetone. The drained resin is then removed and the 3 liters of combined organic solvent are 15 evaporated to dryness in a rotary evaporator under vacuum. The evaporation residue (17.7 g) is slurried in 50 ml of methanol, the suspension obtained is centrifuged at 3 000 rpm for 15 minutes and the settled 20 supernatant obtained constitutes the culture supernatant extract. This extract is tested in dilution for inhibition of the binding to the PBR receptor, and gives an activity evaluated at 1/200 (50% inhibition). 25 The combined biomasses (199 g) in a 2 liter beaker are treated, with stirring, with a mixture of 750 ml of methylene chloride and 750 ml of methanol. Stirring is continued for 15 hours at room temperature.
18 The suspension is then filtered and the clear solution obtained is concentrated under vacuum in a rotary evaporator. The evaporation residue (5.4 g) is then slurried in 50 ml of methanol and constitutes the 5 biomass extract. This extract is tested for inhibition of the binding of the PBR receptor, and gives an activity measured at 1/2200 (ID 50 = 2200-1). EXAMPLE B SRL 5186 10 With the same respective protocols and media: - agar medium for the subculturings on Petri dishes - liquid preculture medium - liquid production medium, 14 x 500 ml conical flasks containing 100 ml of 15 production medium, and inoculated to 5%, are incubated at 28 0 C in a warm chamber on a rotary shaker rotating at 210 rpm, for 6 days. After centrifugation and storage of the production supernants and biomasses for one to two days 20 in a freezer at -20 0 C, these products are thawed before proceeding with their extraction. The biomasses (54.9 g) are treated in a beaker, with stirring, with a mixture of 250 ml of dichloromethane and 250 ml of methanol, for ten hours. 25 The suspension is then filtered and the clear solution obtained is concentrated to dryness on a rotary evaporator.
19 The dry residue (1.4 g) is slurried in 17.5 ml of methanol and the suspension obtained is centrifuged at 3 000 rpm for 15 minutes. The centrifugation supernatant collected constitutes the 5 biomass extract. This extract, evaluated in dilution on the test for inhibition of binding to the PBR receptor, gives a 50% inhibition in the test at a dilution of 1/3750 (ID 50 = 3 7501). 10 160 g of XAD 16 polystyrene-divinylbenzene resin (Rohm & Haas) are added to the 1 400 ml of thawed supernatant and the suspension is stirred for 15 hours. The resin is filtered off, the filtrate is removed and the resin is retreated with 200 ml of solution 15 containing 25% methanol in water for 3 hours. The resin is filtered off and this second filtrate is removed. The resin then undergoes three similar treatments, two with 200 ml of methanol and the last with 200 ml of acetone. These last three filtrates 20 are combined in a round-bottomed flask and then concentrated under vacuum on a rotary evaporator. The dry residue obtained (2.2 g) is then slurried in 17.5 ml of methanol and the solution obtained constitutes the supernatant extract. 25 This extract, evaluated in dilution on the test for inhibition of the binding to the PBR receptor, gives a 50% inhibition at a dilution of 1/940 (ID 50 940 ).
20 EXAMPLE C SRL 5189 With the same respective protocols and media: - agar medium for the subculturings on Petri dishes - liquid preculture medium 5 - liquid production medium, 10 x 500 ml conical flasks containing 100 ml of production medium, inoculated to 5%, are incubated at 28 0 C in a warm chamber on a rotary shaker rotating at 210 rpm, for 8 days. 10 After centrifugation and storage of the production supernants and biomasses for one to two days in a freezer at -20 0 C, these products are thawed before proceeding with their extraction. The biomasses (69.5 g) are treated in a 15 beaker, with stirring, with a mixture of 150 ml of dichloromethane and 150 ml of methanol, for ten hours. The suspension is then filtered and the clear solution obtained is concentrated to dryness on a rotary evaporator. The dry residue (1.5 g) is slurried in 20 12.5 ml of methanol and the solution obtained is centrifuged at 3 000 rpm for 15 minutes. The centrifugation supernatant collected constitutes the biomass extract. This extract, evaluated in dilution on the test for inhibition of the binding to the PBR 25 receptor, gives a 50% inhibition in the test at a dilution of 1/2600 (ID 50 = 2 600-'). 100 g of XAD 16 polystyrene-divinylbenzene resin (Rohm & Haas) are added to the 1 000 ml of thawed 21 supernatant and the suspension is stirred for 15 hours. The resin is filtered off, the filtrate is removed and the resin is retreated with 150 ml of a solution containing 25% methanol in water, for 3 hours. The 5 resin is filtered off and this second filtrate is removed. The resin then undergoes three similar treatments, two with 150 ml of methanol and the last with 150 ml of acetone. These last three filtrates are combined in a round-bottomed flask and then 10 concentrated under vacuum on a rotary evaporator. The dry residue obtained (1.7 g) is then slurried in 12.5 ml of methanol and the solution obtained constitutes the supernatant extract. This extract, evaluated in dilution on the 15 test for inhibition of the binding to the PBR receptor, gives a 50% inhibition at a dilution of 1/600 (ID 50 500-') In the compositions according to the invention, the substance which binds to PBR is 20 preferably used in an amount ranging from 0.00001 to 20% by weight relative to the total weight of the composition and in particular in an amount ranging from 0.001% to 10% by weight relative to the total weight of the composition. 25 The compositions according to the invention may be in any presentation form normally used for topical application.
22 The amounts of the various constituents in the compositions according to the invention are those conventionally used in the fields under consideration and are appropriate for their presentation form. 5 For a topical application, the compositions of the invention comprise a medium which is compatible with the skin. These compositions may especially be in the form of aqueous, alcoholic or aqueous-alcoholic solutions, gels, water-in-oil or oil-in-water emulsions 10 having the appearance of a cream or a gel, micro emulsions or aerosols, or alternatively in the form of vesicular dispersions containing ionic and/or nonionic lipids. These presentation forms are prepared according to the usual methods of the fields under consideration. 15 These compositions for topical application may in particular constitute a cosmetic or dermatological protective, treatment or care composition for the face, for the neck, for the hands or for the body (for example day creams, night creams, 20 antisun creams or oils or body milks), a make-up composition (for example a foundation) or an artificial tanning composition. When the composition of the invention is an emulsion, the proportion of fatty substances it 25 contains may range from 5% to 80% by weight and preferably from 5% to 50% by weight relative to the total weight of the composition. The fatty substances and emulsifiers used in the composition in emulsion 23 form are chosen from those conventionally used in cosmetics or dermatology. As fatty substances which may be used in the invention, mention may be made of mineral oils 5 (petroleum jelly), plant oils (liquid fraction of karite butter) and hydrogenated derivatives thereof, animal oils, synthetic oils (perhydrosqualene), silicone oils (polydimethylsiloxane) and fluoro oils. Other fatty substances which may also be mentioned 10 included fatty alcohols (cetyl alcohol or stearyl alcohol), fatty acids (stearic acid) and waxes. The emulsifiers may be present in the composition in a proportion ranging from 0.3% to 30% by weight and preferably from 0.5% to 30% by weight 15 relative to the total weight of the composition. In a known manner, the cosmetic or dermatological compositions of the invention may also contain adjuvants that are common in the corresponding fields, such as hydrophilic or lipophilic gelling 20 agents, preserving agents, antioxidants, solvents, fragrances, fillers, screening agents and dyestuffs. Moreover, these compositions may contain hydrophilic or lipophilic active agents. The amounts of these various adjuvants or active agents are those conventionally 25 used in cosmetics or dermatology, and, for example, from 0.01% to 20% of the total weight of the composition. Depending on their nature, these adjuvants or these active agents may be introduced into the fatty 24 phase, into the aqueous phase and/or into the lipid vesicles. Among the active agents which the compositions of the invention may contain, mention may 5 be made in particular of active agents which have an effect on treating wrinkles or fine lines, and in particular keratolytic active agents. The term "keratolytic" means an active agent which has desquamating, exfoliant or scrubbing properties, or an 10 active agent capable of softening the horny layer. Among these active agents with an effect on treating wrinkles and fine lines, which the compositions of the invention may contain, mention may be made in particular of hydroxy acids and retinoids. 15 The hydroxy acids may be, for example, a-hydroxy acids or f-hydroxy acids, which may be linear, branched or cyclic, and saturated or unsaturated. The hydrogen atoms of the carbon chain may also be substituted with halogens, halogenated, alkyl, 20 acyl, acyloxy, alkoxycarbonyl or alkoxy radicals containing from 2 to 18 carbon atoms. The hydroxy acids which may be used are, in particular, glycolic acid, lactic acid, malic acid, tartaric acid, citric acid, 2-hydroxyalkanoic acid, 25 mandelic acid, salicylic acid and the alkyl derivatives thereof, for instance 5-n-octanoylsalicylic acid, 5-n-dodecanoylsalicylic acid, 5-n-decanoylsalicylic acid, 5-n-octylsalicylic acid, 5-n-heptyloxysalicylic 25 acid or 4-n-heptyloxysalicylic acid, and 2-hydroxy 3-methylbenzoic acid or alkoxylated derivatives thereof, for instance 2-hydroxy-3-methoxybenzoic acid. The retinoids may be in particular retinoic 5 acid and derivatives thereof, retinol (vitamin A) and esters thereof such as retinyl palmitate, retinyl acetate or retinyl propionate, and salts thereof. These active agents may be used in particular in concentrations ranging from 0.0001% to 5% by weight 10 relative to the total weight of the composition.
Claims (15)
1. Use of at least one substance which binds to the peripheral benzodiazepine receptor, or PBR, for the manufacture of a cosmetic, pharmacological 5 or dermatological topical composition in the treatment of cutaneous stress.
2. Use of at least one substance which binds to PBR for the manufacture of a cosmetic and/or dermatological topical composition for reducing 10 wrinkles, reducing solar erythema or protecting against free radicals.
3. Use according to either of Claims 1 and 2, characterized in that the substance which binds to PBR is a PBR agonist chosen from synthetic molecules, 15 natural extraction substances and a substance obtained by fermentation.
4. Use according to any one of Claims 1 to 3, characterized in that the substance which binds to PBR is Ro 5-4864. 20
5. Use according to any one of Claims 1 to 3, characterized in that the substance which binds to PBR is a substance obtained by fermentation.
6. Use according to any one of Claims 1 to 5, characterized in that the substance is present in 25 the cosmetic or dermatological composition in an amount ranging from 0.00001% to 20% by weight relative to the total weight of the composition. 27
7. Use according to any one of Claims 1 to 6, characterized in that the agonist substance is present in the cosmetic or dermatological composition in an amount ranging from 0.001% to 10% by weight 5 relative to the total weight of the composition.
8. Use according to any one of Claims 1 to 7, characterized in that the composition also contains a hydroxy acid and/or a retinoid.
9. Use according to Claim 8, characterized 10 in that the hydroxy acid is chosen from a-hydroxy acids and $-hydroxy acids, which may be linear, branched or cyclic, and saturated or unsaturated.
10. Use according to Claim 9, characterized in that the retinoid is chosen from the group 15 comprising retinoic acid and derivatives thereof and retinol and esters thereof.
11. Cosmetic and/or dermatological topical composition, characterized in that it contains a substance which binds to PBR as active principle. 20
12. Strain Nocardia species SRL 4988 filed at the C.N.C.M. of the Institut Pasteur under No. 1-2305 and its productive mutants.
13. Strain Streptomyces species SRL 5186 filed at the C.N.C.M. of the Institut Pasteur under 25 No. 1-2306 and its productive mutants.
14. Strain Actinosinnema species SRL 5189 filed at the C.N.C.M. of the Institut Pasteur under No. 1-2307 and its productive mutants. 28
15. Cosmetic and/or dermatological topical composition, characterized in that it contains a substance obtained by fermenting a strain according to Claims 12 to 14 as active substance.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9814387A FR2785803B1 (en) | 1998-11-17 | 1998-11-17 | USE OF A SUBSTANCE BINDING TO THE PERIPHERAL RECEPTOR OF BENZODIAZEPINES IN THE TREATMENT OF SKIN STRESS |
FR98/14387 | 1998-11-17 | ||
PCT/FR1999/002761 WO2000028947A2 (en) | 1998-11-17 | 1999-11-10 | Use of a substance binding with the peripheral benzodiazepin receptor for treating skin stress |
Publications (2)
Publication Number | Publication Date |
---|---|
AU1166100A true AU1166100A (en) | 2000-06-05 |
AU764786B2 AU764786B2 (en) | 2003-08-28 |
Family
ID=9532791
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU11661/00A Ceased AU764786B2 (en) | 1998-11-17 | 1999-11-10 | Use of a substance binding with the peripheral benzodiazepin receptor for treating skin stress |
Country Status (18)
Country | Link |
---|---|
US (2) | US6767533B1 (en) |
EP (1) | EP1131039B1 (en) |
JP (1) | JP2002529486A (en) |
KR (1) | KR20010089475A (en) |
AT (1) | ATE298230T1 (en) |
AU (1) | AU764786B2 (en) |
CA (1) | CA2349919A1 (en) |
CY (1) | CY1105144T1 (en) |
DE (1) | DE69925928T2 (en) |
DK (1) | DK1131039T3 (en) |
ES (1) | ES2244246T3 (en) |
FR (1) | FR2785803B1 (en) |
HK (1) | HK1037966A1 (en) |
HR (1) | HRP20010367A2 (en) |
HU (1) | HUP0105058A2 (en) |
PT (1) | PT1131039E (en) |
SI (1) | SI1131039T1 (en) |
WO (1) | WO2000028947A2 (en) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7125866B1 (en) * | 1999-04-30 | 2006-10-24 | Regents Of The University Of Michigan | Therapeutic applications of pro-apoptotic benzodiazepines |
ES2246588T3 (en) * | 1998-12-18 | 2006-02-16 | Scios Inc. | TREATMENT OF DISEASES INVOLVING CYST FORMATION. |
US20050113460A1 (en) * | 1999-04-30 | 2005-05-26 | The Regents Of The University Of Michigan | Compositions and methods relating to novel compounds and targets thereof |
US20060025388A1 (en) | 1999-04-30 | 2006-02-02 | Glick Gary D | Compositions and methods relating to novel compounds and targets thereof |
US20030119029A1 (en) * | 1999-04-30 | 2003-06-26 | Regents Of The University Of Michigan | Compositions and methods relating to novel benzodiazepine compounds and targets thereof |
US7572788B2 (en) | 1999-04-30 | 2009-08-11 | The Regents Of The University Of Michigan | Compositions and methods relating to novel compounds and targets thereof |
US7276348B2 (en) * | 1999-04-30 | 2007-10-02 | Regents Of The University Of Michigan | Compositions and methods relating to F1F0-ATPase inhibitors and targets thereof |
US20040176358A1 (en) * | 1999-04-30 | 2004-09-09 | The Regents Of The University Of Michigan | Compositions and methods relating to novel compounds and targets thereof |
DE10021468A1 (en) * | 2000-05-04 | 2001-11-08 | Basf Ag | Use of PARP inhibitors in cosmetic preparations |
MXPA05002871A (en) | 2002-09-20 | 2005-10-05 | Arrow Therapeutics Ltd | Benzodiazepine derivatives and pharmaceutical compositions containing them. |
US20050272723A1 (en) * | 2004-04-27 | 2005-12-08 | The Regents Of The University Of Michigan | Methods and compositions for treating diseases and conditions associated with mitochondrial function |
US20060052369A1 (en) * | 2004-09-07 | 2006-03-09 | The Regents Of The University Of Michigan | Compositions and methods relating to novel compounds and targets thereof |
FR2879451B1 (en) * | 2004-12-20 | 2007-05-04 | Oreal | USE OF BENZODIAZEPINE RECEPTOR LIGANDS TO FIGHT AGING SIGNS |
WO2006067327A2 (en) * | 2004-12-20 | 2006-06-29 | L'oreal | Benzodiazepine peripheral receptor antagonists for treating dry skin |
FR2879450B1 (en) * | 2004-12-20 | 2007-02-09 | Oreal | ANTAGONISTS OF PERIPHERAL RECEPTORS OF BENZODIAZEPINES FOR THE TREATMENT OF DRY SKINS |
JP2008524177A (en) * | 2004-12-20 | 2008-07-10 | ロレアル | Use of benzodiazepine receptor ligands to combat aging signs |
US7638624B2 (en) | 2005-01-03 | 2009-12-29 | The Regents Of The University Of Michigan | Compositions and methods relating to novel benzodiazepine compounds and derivatives |
US20070043033A1 (en) * | 2005-06-01 | 2007-02-22 | The Regents Of The University Of Michigan | Unsolvated benzodiazepine compositions and methods |
EP2604269B1 (en) | 2005-11-01 | 2014-09-24 | The Regents Of The University Of Michigan | 1,4-benzodiazepine-2,5-diones with therapeutic properties |
KR20070058291A (en) * | 2005-12-02 | 2007-06-08 | 엘지전자 주식회사 | Recording medium, method and apparatus for recording management information on the recording medium |
US7759338B2 (en) * | 2006-04-27 | 2010-07-20 | The Regents Of The University Of Michigan | Soluble 1,4 benzodiazepine compounds and stable salts thereof |
NZ573452A (en) | 2006-06-09 | 2011-09-30 | Univ Michigan | Compositions and methods relating to novel compounds and targets thereof |
US20100021928A1 (en) * | 2006-06-26 | 2010-01-28 | Technion Research & Development Foundation Ltd. | Methods and kits for diagnosing cancer |
NZ579507A (en) | 2007-03-09 | 2011-11-25 | Univ Michigan | Compositions and methods relating to novel compounds and targets thereof |
JP5539875B2 (en) * | 2007-08-31 | 2014-07-02 | アルキメデス・デベロップメント・リミテッド | Non-aqueous pharmaceutical composition |
AU2008298870C1 (en) | 2007-09-14 | 2014-10-09 | The Regents Of The University Of Michigan | F1F0-ATPase inhibitors and related methods |
CN101918375A (en) | 2007-11-06 | 2010-12-15 | 密歇根大学董事会 | Benzodiazepinone compounds useful in the treatment of skin conditions |
US8497307B2 (en) | 2008-09-11 | 2013-07-30 | The Regents Of The University Of Michigan | Aryl guanidine F1F0-ATPase inhibitors and related methods |
WO2010121164A2 (en) | 2009-04-17 | 2010-10-21 | The Regents Of The University Of Michigan | 1,4-benzodiazepinone compounds and their use in treating cancer |
US9075060B2 (en) | 2009-06-16 | 2015-07-07 | Technion Research & Development Foundation Limited | Methods for diagnosing oral or oral-pharyngeal cancer |
EP2470020A4 (en) | 2009-09-18 | 2013-03-13 | Univ Michigan | Benzodiazepinone compounds and methods of treatment using same |
JP5856063B2 (en) | 2009-11-17 | 2016-02-09 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | 1,4-Benzodiazepine-2,5-dione and related compounds having therapeutic properties |
CN102753544A (en) | 2009-11-17 | 2012-10-24 | 密执安大学评议会 | 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5279082A (en) * | 1975-12-25 | 1977-07-02 | Green Cross Corp:The | Preparation of anti-tumor compound |
JPS5473195A (en) * | 1977-11-22 | 1979-06-12 | Takeda Chem Ind Ltd | Preparation of tomaymycins |
JPS56121495A (en) * | 1980-02-29 | 1981-09-24 | Kyowa Hakko Kogyo Co Ltd | Preparation of benzodiazepine derivative |
IL101387A (en) * | 1992-03-26 | 1999-11-30 | Pharmos Ltd | Emulsion with enhanced topical and/or transdermal systemic effect utilizing submicron oil droplets |
WO1994002176A1 (en) * | 1992-07-28 | 1994-02-03 | The Procter & Gamble Company | Pharmaceutical composition for topical use containing a crosslinked cationic polymer and an alkoxylated ether |
US7125866B1 (en) * | 1999-04-30 | 2006-10-24 | Regents Of The University Of Michigan | Therapeutic applications of pro-apoptotic benzodiazepines |
-
1998
- 1998-11-17 FR FR9814387A patent/FR2785803B1/en not_active Expired - Fee Related
-
1999
- 1999-11-10 JP JP2000581995A patent/JP2002529486A/en not_active Withdrawn
- 1999-11-10 KR KR1020017006238A patent/KR20010089475A/en active IP Right Grant
- 1999-11-10 HU HU0105058A patent/HUP0105058A2/en unknown
- 1999-11-10 SI SI9930814T patent/SI1131039T1/en unknown
- 1999-11-10 ES ES99972094T patent/ES2244246T3/en not_active Expired - Lifetime
- 1999-11-10 EP EP99972094A patent/EP1131039B1/en not_active Expired - Lifetime
- 1999-11-10 DK DK99972094T patent/DK1131039T3/en active
- 1999-11-10 AU AU11661/00A patent/AU764786B2/en not_active Ceased
- 1999-11-10 DE DE69925928T patent/DE69925928T2/en not_active Expired - Fee Related
- 1999-11-10 CA CA002349919A patent/CA2349919A1/en not_active Abandoned
- 1999-11-10 PT PT99972094T patent/PT1131039E/en unknown
- 1999-11-10 US US09/831,720 patent/US6767533B1/en not_active Expired - Fee Related
- 1999-11-10 WO PCT/FR1999/002761 patent/WO2000028947A2/en not_active Application Discontinuation
- 1999-11-10 AT AT99972094T patent/ATE298230T1/en not_active IP Right Cessation
-
2001
- 2001-05-17 HR HR20010367A patent/HRP20010367A2/en not_active Application Discontinuation
- 2001-12-11 HK HK01108691A patent/HK1037966A1/en not_active IP Right Cessation
-
2004
- 2004-07-26 US US10/898,793 patent/US20050090489A1/en not_active Abandoned
-
2005
- 2005-09-21 CY CY20051101175T patent/CY1105144T1/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2000028947A3 (en) | 2000-08-03 |
EP1131039B1 (en) | 2005-06-22 |
WO2000028947A2 (en) | 2000-05-25 |
HUP0105058A2 (en) | 2002-05-29 |
FR2785803B1 (en) | 2005-03-25 |
DE69925928T2 (en) | 2006-08-17 |
DE69925928D1 (en) | 2005-07-28 |
PT1131039E (en) | 2005-11-30 |
ES2244246T3 (en) | 2005-12-01 |
SI1131039T1 (en) | 2005-10-31 |
EP1131039A2 (en) | 2001-09-12 |
AU764786B2 (en) | 2003-08-28 |
CY1105144T1 (en) | 2010-03-03 |
ATE298230T1 (en) | 2005-07-15 |
HRP20010367A2 (en) | 2002-06-30 |
KR20010089475A (en) | 2001-10-06 |
US6767533B1 (en) | 2004-07-27 |
DK1131039T3 (en) | 2005-10-17 |
US20050090489A1 (en) | 2005-04-28 |
HK1037966A1 (en) | 2002-03-01 |
JP2002529486A (en) | 2002-09-10 |
FR2785803A1 (en) | 2000-05-19 |
CA2349919A1 (en) | 2000-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU764786B2 (en) | Use of a substance binding with the peripheral benzodiazepin receptor for treating skin stress | |
US6562355B1 (en) | Comixture of dextran sulfate/escin for treating skin redness/edema and/or sensitive skin | |
JP2941778B2 (en) | Compositions comprising microbial media and uses thereof | |
JP5721619B2 (en) | Cosmetic composition comprising exopolysaccharides derived from microbial mats and uses thereof | |
US8722108B2 (en) | Cosmetic and/or pharmaceutical composition comprising an extract of carob as active agent for activating aquaporin expression | |
US11759544B2 (en) | Therapeutic compositions for enhanced healing of wounds and scars | |
US7674451B2 (en) | Cosmetic or pharmaceutical composition comprising peptides, uses and treatment processes | |
US20010046509A1 (en) | Use of cinnamic acid or of its derivatives in a cosmetic firming composition | |
US20040142873A1 (en) | Cosmetic or dermatological use of peptides for promoting adhesion between skin cells | |
CN103415531A (en) | Peptide for use in the treatment of skin conditions | |
CN113559238A (en) | A pharmaceutical or cosmetic containing active peptide and having antiaging effect | |
US5917088A (en) | Salicyclic acid derivatives, process of preparation and uses thereof | |
US20040141939A1 (en) | Cosmetic or dermatological use of peptides for promoting adhesion between skin cells | |
US6660283B2 (en) | Use of cinnamic acid, or of at least one of its derivatives in a cosmetic composition | |
US6264962B1 (en) | Use of cinnamic acid or of at least one of its derivatives in a cosmetic composition | |
CA3235725A1 (en) | Biosurfactant formulations for use in skincare and wound treatment | |
KR20070031472A (en) | Use of a Substance Binding with the Peripheral Benzodiazepin Receptor for Treating Skin Stress | |
US7737119B2 (en) | Cosmetic or pharmaceutical composition comprising peptides, uses and treatment processes | |
AU619399B2 (en) | Cosmetic composition containing compounds obtained by the culture of cells, especially fibroblasts or keratinocytes | |
WO2023196763A1 (en) | Therapeutic compositions for enhanced healing of wounds and scars | |
BR112015017934B1 (en) | USE OF A LACTOBACILLUS DELBRUECKII EXTRACT, PLANT CELL ELICITATION PROCESS AND PREPARATION OF A COMPOSITION, COMPOSITIONS, COSMETIC COMPOSITION AND USES OF COSMETIC COMPOSITION | |
WO2023192979A2 (en) | Compositions and methods for promoting hair growth | |
JPH0348166B2 (en) | ||
MXPA00000493A (en) | Cosmetic compositions | |
MXPA97010478A (en) | Use of an abstract of a non-photosintetic filamentosa bacteria and composition that the conti |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FGA | Letters patent sealed or granted (standard patent) |